STENTiT, a medical device company bringing a novel class of regenerative endovascular implants for treatment of cardiovascular diseases, has announced the appointment of its medical advisory board, chaired by Patrick Serruys (National University of Ireland, Galway, Ireland) and complemented by Marc van Sambeek (Eindhoven University of Technology, Eindhoven, The Netherlands) and Yoshinobu Onuma (National University of Ireland, Galway, Ireland).
STENTiT is a medical device spin-off company from the Dutch Eindhoven University of Technology, focusing on the development of regenerative endovascular implants. These bioresorbable devices trigger a natural healing response by the circulating blood cells, in which the implant is being replaced by new vascular tissue to restore the artery from the inside-out.
Bart Sanders, CEO of STENTiT, said: “We are excited to receive the support of these highly esteemed professionals in the current stage of our company development.”
“What is fascinating about STENTiT’s technology, is the presence of endoluminal elastin in early preclinical work. Restoring this protective layer in patients would be a unique approach to prevent late-stage neo-atherosclerosis,” says Serruys.
“Providing a new regenerative inner surface of the vessel, may be key to improve patency outcomes in peripheral interventions, where so far current alternatives are suboptimal,” adds van Sambeek, vascular surgeon at the Catherina Hospital in Eindhoven, the Netherlands, and part-time professor of Application of Engineering in Vascular Surgery and Endovascular Therapy from the department of Biomedical Engineering at the Eindhoven University of Technology.
“STENTiT will be one of the unique technologies to overcome the limitations of first generation resorbable devices,” states Onuma, professor of interventional cardiology and medical director of Coronary Imaging and Atherosclerosis Research of the CORRIB Core Lab from the National University of Ireland Galway.
Bart Sanders further concludes: ”In the ongoing quest to improve sustained vascular patency, regenerative stents provide a unique approach in combining regenerative medicine with bioresorbable stent technology. By providing temporary scaffolding while simultaneously restoring the artery from the inside-out, we could significantly improve durable clinical outcomes.”